290 related articles for article (PubMed ID: 37201112)
61. Characterization of Gut Microbiota and Exploration of Potential Predictive Model for Hepatocellular Carcinoma Microvascular Invasion.
Zhang N; Wang Z; Lv J; Zhang S; Liu Y; Liu T; Li W; Gong L; Zhang X; El-Omar EM; Lu W
Front Med (Lausanne); 2022; 9():836369. PubMed ID: 35372388
[TBL] [Abstract][Full Text] [Related]
62. The Immunologic Role of Gut Microbiota in Patients with Chronic HBV Infection.
Yang R; Xu Y; Dai Z; Lin X; Wang H
J Immunol Res; 2018; 2018():2361963. PubMed ID: 30148173
[TBL] [Abstract][Full Text] [Related]
63. Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma.
Pratap Singh R; Kumari N; Gupta S; Jaiswal R; Mehrotra D; Singh S; Mukherjee S; Kumar R
Microbiol Spectr; 2023 Aug; 11(4):e0459622. PubMed ID: 37409975
[TBL] [Abstract][Full Text] [Related]
64. Distinctly altered gut microbiota in the progression of liver disease.
Xie G; Wang X; Liu P; Wei R; Chen W; Rajani C; Hernandez BY; Alegado R; Dong B; Li D; Jia W
Oncotarget; 2016 Apr; 7(15):19355-66. PubMed ID: 27036035
[TBL] [Abstract][Full Text] [Related]
65. Operable hepatitis B virus-related hepatocellular carcinoma: gut microbiota profile of patients at different ages.
Peng YC; Xu JX; Zeng CF; Zhao XH; You XM; Xu PP; Li LQ; Qi LN
Ann Transl Med; 2022 Apr; 10(8):477. PubMed ID: 35571398
[TBL] [Abstract][Full Text] [Related]
66. Gut Microbiome and Serum Metabolome Alterations Associated with Isolated Dystonia.
Ma L; Keng J; Cheng M; Pan H; Feng B; Hu Y; Feng T; Yang F
mSphere; 2021 Aug; 6(4):e0028321. PubMed ID: 34346706
[TBL] [Abstract][Full Text] [Related]
67. Clinical Significance of B7-H3 Expression During the Progression of Hepatitis B Virus Infection.
Gao F; Xu JC; Zhu L; Chen H; Zhu XY; You XR; Li SX; Zhu CL; Yang C; Zhu CW; Xu P
Viral Immunol; 2018 Dec; 31(10):668-675. PubMed ID: 30481143
[TBL] [Abstract][Full Text] [Related]
68. Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy.
Kang Y; Cai Y
J Hosp Infect; 2017 Aug; 96(4):342-348. PubMed ID: 28545829
[TBL] [Abstract][Full Text] [Related]
69. Influences of non-IgE-mediated cow's milk protein allergy-associated gut microbial dysbiosis on regulatory T cell-mediated intestinal immune tolerance and homeostasis.
Wang J; Zheng S; Yang X; Huazeng B; Cheng Q
Microb Pathog; 2021 Sep; 158():105020. PubMed ID: 34089791
[TBL] [Abstract][Full Text] [Related]
70. Characteristics and Clinical Significance of Intestinal Microbiota in Patients with Chronic Hepatitis B Cirrhosis and Type 2 Diabetes Mellitus.
Sun X; Chi X; Zhao Y; Liu S; Xing H
J Diabetes Res; 2022; 2022():1826181. PubMed ID: 35601017
[TBL] [Abstract][Full Text] [Related]
71. MicroRNA-138 Regulates T-Cell Function by Targeting PD-1 in Patients with Hepatitis B Virus-Related Liver Diseases.
Liu W; Zheng X; Wang J; He Q; Li J; Zhang Z; Liu H
Lab Med; 2021 Sep; 52(5):439-451. PubMed ID: 33410459
[TBL] [Abstract][Full Text] [Related]
72. Dysbiosis of Gut Microbiota Is Associated With the Progression of Radiation-Induced Intestinal Injury and Is Alleviated by Oral Compound Probiotics in Mouse Model.
Zhao TS; Xie LW; Cai S; Xu JY; Zhou H; Tang LF; Yang C; Fang S; Li M; Tian Y
Front Cell Infect Microbiol; 2021; 11():717636. PubMed ID: 34760714
[TBL] [Abstract][Full Text] [Related]
73. Gut microbiota: A new piece in understanding hepatocarcinogenesis.
Zhou A; Tang L; Zeng S; Lei Y; Yang S; Tang B
Cancer Lett; 2020 Apr; 474():15-22. PubMed ID: 31917160
[TBL] [Abstract][Full Text] [Related]
74. Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients.
Chung MW; Kim MJ; Won EJ; Lee YJ; Yun YW; Cho SB; Joo YE; Hwang JE; Bae WK; Chung IJ; Shin MG; Shin JH
World J Gastroenterol; 2021 Nov; 27(42):7340-7349. PubMed ID: 34876793
[TBL] [Abstract][Full Text] [Related]
75. High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection.
Gu S; Fu X; Ye G; Chen C; Li X; Zhong S; Tang L; Chen H; Jiang D; Hou J; Li Y
Front Immunol; 2021; 12():649197. PubMed ID: 34234772
[TBL] [Abstract][Full Text] [Related]
76. Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma.
Hong B; Qian Y; Zhang H; Sang YW; Cheng LF; Wang Q; Gao S; Zheng M; Yao HP
World J Gastroenterol; 2016 May; 22(18):4538-46. PubMed ID: 27182163
[TBL] [Abstract][Full Text] [Related]
77. Overrepresentation of IL-10-Expressing B Cells Suppresses Cytotoxic CD4+ T Cell Activity in HBV-Induced Hepatocellular Carcinoma.
Xue H; Lin F; Tan H; Zhu ZQ; Zhang ZY; Zhao L
PLoS One; 2016; 11(5):e0154815. PubMed ID: 27136203
[TBL] [Abstract][Full Text] [Related]
78. Single-nodule hepatitis B virus-associated hepatocellular carcinoma smaller than 3 cm: two phenotypes defined by cluster analysis and their association with the outcome of ablation as the first-line therapy.
Chen S; Wu Y; Qi H; Shen L; Ma W; Cao F; Diao Y; Wang T; Ou S; Fan W
Int J Hyperthermia; 2021; 38(1):120-129. PubMed ID: 33541160
[TBL] [Abstract][Full Text] [Related]
79. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma.
Han YF; Zhao J; Ma LY; Yin JH; Chang WJ; Zhang HW; Cao GW
World J Gastroenterol; 2011 Oct; 17(38):4258-70. PubMed ID: 22090781
[TBL] [Abstract][Full Text] [Related]
80. HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity.
Meng F; Zhen S; Song B
APMIS; 2017 Aug; 125(8):743-751. PubMed ID: 28493520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
